Pharmacokinetics, Pharmacodynamics, and Tolerability of Opicapone in Healthy Chinese and Caucasian Subjects: An Open-Label, Single-Center, Phase 1 Study

被引:1
|
作者
Cong, Duanduan [1 ]
Song, Jie [2 ]
Liu, Yue [1 ]
Tan, Yan [2 ]
Xue, Wei [1 ]
Liu, Xiaohui [1 ]
Qi, Wenyuan [1 ]
Lu, Jun [2 ]
Yuan, Xiaojuan [3 ]
Zhou, Yongchun [3 ]
Hui, Ai-Min [2 ]
Li, Kexin [1 ]
机构
[1] Chinese Acad Med Sci, Clin Trial Ctr, Beijing Hosp, Natl Ctr Gerontol,Inst Geriatr Med,Assessment Cli, 1 Dahua Rd, Beijing 100005, Peoples R China
[2] Shanghai Fosun Pharmaceut Dev Co Ltd, Clin Res Dept, Shanghai 200000, Peoples R China
[3] Wanbang Biopharmaceut Co Ltd, Xuzhou, Jiangsu, Peoples R China
关键词
Clinical trial; COMT inhibitor; Ethnicity; Opicapone; Pharmacodynamics; Pharmacokinetics; Tolerability; CATECHOL-O-METHYLTRANSFERASE; PARKINSONS-DISEASE; MOTOR FLUCTUATIONS; LEVODOPA; INHIBITORS; DISCOVERY; THERAPY; ADJUNCT; LIVER;
D O I
10.1007/s40120-021-00314-8
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction This study evaluated the pharmacokinetics (PK) and pharmacodynamics (PD) of single and multiple doses of opicapone (OPC) in healthy Chinese and Caucasian subjects. Methods In this open-label, single-center, phase 1 study, eligible Chinese subjects received one of three OPC doses (25, 50, or 100 mg), and Caucasian subjects received either 25 or 50 mg of OPC. All subjects were administered a single dose of OPC, whereas subjects in the 50-mg OPC group continued to receive once-daily doses of 50 mg OPC for 10 days. The primary endpoint was to evaluate and compare the plasma concentrations and PK parameters of OPC and its main metabolite, and erythrocyte-soluble catechol-O-methyltransferase (S-COMT) activity in Chinese subjects with that of Caucasian subjects. The secondary endpoint was to evaluate the safety of OPC in Chinese subjects. The estimated results for geometric mean ratios (GMRs) were evaluated with the standard bioequivalence (BE) limits between 80% and 125% to evaluate the ethnic differences. All statistical analyses were performed using SAS version 9.4. Results In total, 70 subjects (45 Chinese, 25 Caucasian) were enrolled; the majority of them were male (85.7%). The plasma exposure of both OPC and BIA 9-1103 increased in an approximately dose-proportional manner in both populations. Maximum S-COMT inhibition ranged from 79% to 95% after a single dose and was about 94% after a 10-day once-daily regimen in both populations. The point estimates of GMRs (Chinese/Caucasian) and 90% CI, except C-max in 25-mg and 50-mg OPC groups, for PK and PD parameters were within 80% to 125%. Furthermore, no new risks or safety concerns associated with OPC were identified, indicating a tolerable safety profile in healthy Chinese subjects. Conclusion Ethnicity had no significant impact on PK and PD parameters after single or multiple doses of OPC, and OPC was safe and tolerable in healthy Chinese subjects.
引用
收藏
页码:283 / 301
页数:19
相关论文
共 50 条
  • [1] Pharmacokinetics, Pharmacodynamics, and Tolerability of Opicapone in Healthy Chinese and Caucasian Subjects: An Open-Label, Single-Center, Phase 1 Study
    Duanduan Cong
    Jie Song
    Yue Liu
    Yan Tan
    Wei Xue
    Xiaohui Liu
    Wenyuan Qi
    Jun Lu
    Xiaojuan Yuan
    Yongchun Zhou
    Ai-Min Hui
    Kexin Li
    [J]. Neurology and Therapy, 2022, 11 : 283 - 301
  • [2] Pharmacokinetics, Safety, and Tolerability of Tenapanor in Healthy Chinese and Caucasian Volunteers: A Randomized, Open-Label, Single-Center, Placebo-Controlled Phase 1 Study
    Yuan, Gang
    Chen, Yili
    Li, Li
    Wang, Xin
    Wei, Gang
    Zeng, Jiawei
    Hui, Ai-Min
    Jiang, Yueyun
    Zhao, Han
    Diao, Lei
    Zhou, Yongchun
    Xiao, Yinglian
    Chen, Minhu
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2024, 2024
  • [3] Tolerability and pharmacokinetics of disodium folinate following single intravenous doses in healthy Chinese subjects: an open-label, randomized, single-center study
    Liu, Yani
    Zhou, Jiali
    Li, Zhongfang
    Yang, Chunxiao
    Wu, Jianhong
    Zhang, Yu
    Shi, Shaojun
    Li, Yunqiao
    [J]. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2015, 40 (04) : 443 - 451
  • [4] Tolerability and pharmacokinetics of disodium folinate following single intravenous doses in healthy Chinese subjects: an open-label, randomized, single-center study
    Yani Liu
    Jiali Zhou
    Zhongfang Li
    Chunxiao Yang
    Jianhong Wu
    Yu Zhang
    Shaojun Shi
    Yunqiao Li
    [J]. European Journal of Drug Metabolism and Pharmacokinetics, 2015, 40 : 443 - 451
  • [5] Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Intravenous Siponimod: A Randomized, Open-label Study in Healthy Subjects
    Shakeri-Nejad, Kasra
    Gardin, Anne
    Gray, Cathy
    Neelakantham, Srikanth
    Dumitras, Swati
    Legangneux, Eric
    [J]. CLINICAL THERAPEUTICS, 2020, 42 (01) : 175 - 195
  • [6] Pharmacokinetics and pharmacodynamics of opicapone in healthy Japanese and matched Caucasian subjects
    Rocha, J. -F.
    Falcao, A.
    Lopes, N.
    Santos, A. T.
    Nunes, T.
    Soares-da-Silva, P.
    [J]. MOVEMENT DISORDERS, 2014, 29 : S261 - S261
  • [7] Pharmacokinetics, safety, and tolerability of sodium phenylacetate and sodium benzoate in healthy Japanese volunteers: A phase I, single-center, open-label study
    Endo, Fumio
    Nakamura, Kimitoshi
    Sano, Yuuhei
    Dote, Nobuhito
    Shimizu, Kohei
    Koumura, Emiko
    [J]. DRUG METABOLISM AND PHARMACOKINETICS, 2023, 48
  • [8] Pharmacokinetics, safety, and tolerability of sulcardine sulfate: an open-label, single-dose, randomized study in healthy Chinese subjects
    Chen, Qian
    Qian, Hong-jie
    Wang, Wei
    Zhang, Meng-qi
    Lu, Dong-ying
    Lu, Chuan
    Jin, Jie-mei
    Hu, Chao-ying
    Liu, Gang-yi
    Jia, Jing-ying
    Zheng, Hong-chao
    Li, Xue-ning
    Yu, Chen
    Wang, Yi-ping
    Liu, Yun
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2017, 31 (01) : 120 - 125
  • [9] Pharmacokinetics and Safety of Spesolimab in Healthy Chinese Subjects: An Open-Label, Phase I Study
    Cao, Guoying
    Yang, Haijing
    Wang, Jingjing
    Ishida, Masahiro
    Thoma, Christian
    Haeufel, Thomas
    Bossert, Sebastian
    Zhang, Jing
    [J]. ADVANCES IN THERAPY, 2024, 41 (09) : 3557 - 3568
  • [10] Pharmacokinetics and tolerability of sublingual fentanyl in healthy Japanese and Caucasian volunteers: Phase I, open-label single-dose study
    Lorch, U.
    Farrell, F.
    Kilborn, J.
    Tarnaoka, M.
    Derrick, R.
    Howell, J.
    [J]. PROCEEDINGS OF THE 13TH INTERNATIONAL PAIN CLINIC CONGRESS: WORLD SOCIETY OF PAIN CLINICIANS, 2008, : 131 - +